



# Flow Chemistry-Enabled Divergent and Enantioselective Total Syntheses of Massarinolin A, Purpurolides B, D, E, 2,3- Deoxypurpurolide C, and Structural Revision of Massarinolin A


Ye-Cheng Wang,<sup>[a][b]</sup> Chengsen Cui,<sup>[a][b]</sup> and Mingji Dai<sup>\*[a]</sup>



Massarinolin A  
**(1b, revised)**




Purpurolide B ( $R = \text{OAc}$ )  
Purpurolide D ( $R = \text{OH}$ )  
Purpurolide E ( $R = \text{H}$ )



Purpurolide C (8)


DOI: 10.1002/anie.202109625.




Massarinolin A  
(**1a**, originally proposed)  
antibacterial activity

bicyclo[3.1.1]heptane  
oxaspiro[3.4]octane  
dioxaspiro[4.4]nonane


this work:  
first total synthesis  
structural revision




Massarinolin A  
(**1b**, revised)




Purpurolide B (**2**, R = OAc)  
Purpurolide D (**3**, R = OH)  
Purpurolide E (**4**, R = H)  
pancreatic lipase inhibition



Expansolide A (**5a**, R = Ac)  
Expansolide C (**6a**, R = H)  
Decipienolide A (**7a**, R = X)




Expansolide B (**5b**, R = Ac)  
Expansolide D (**6b**, R = H)  
Decipienolide B (**7b**, R = X)




Purpurolide C (**8**, R = Me)  
Purpurolide F (**9**)  
R: HO<sub>2</sub>C—CH(R)—CH(R)—CH(R)—Me


$\alpha$ -glucosidase inhibition activity



Eutpellacytosporin A (**10a**, 14S)  
Eutpellacytosporin B (**11a**, 14R)










Eutpellacytosporin C (**10b**, 14S)  
Eutpellacytosporin D (**11b**, 14R)





Sporulaminal A (**12a**, 4R)  
Sporulaminal B (**12b**, 4S)




$IC_{50}$ : 4.9 to 17.1  $\mu$ M against DU145, SW1990, Huh7, and PANC-1








catalysts



# COREY-FUCHS ALKYNE SYNTHESIS


(References are on page 566)




### Mechanism:

The mechanism of dibromoolefin formation from the aldehyde is similar to the mechanism of the *Wittig reaction*. However, there is very little known about the formation of the alkyne from the dibromoolefin. The mechanism below is one possible pathway to the observed product.


#### Generation of the phosphorous ylide:




#### Reaction of the phosphorous ylide with the aldehyde:



### Conversion of dibromoolefin to terminal alkyne:






*Liebigs Ann. Chem.* **1970**, 734, 70.


# WOLFF REARRANGEMENT

(References are on page 711)


Wolff (1902):




Preparation of the  $\alpha$ -diazo ketone:





Wolff rearrangement:





Mechanism: <sup>65,9,13</sup>











$\text{Ar} = o\text{-O}_2\text{NC}_6\text{H}_4$

*Tetrahedron Letters*, 1996. 4841.





**Table S9.** Epoxidation for **13c**.

Entry	Reagent	Solvent	T (°C)	Time	Result
1	DBU (3 equiv.), TBHP (5 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	0 to rt	1 d	NR
		CH <sub>2</sub> Cl <sub>2</sub>			
2	DBU (3 equiv.), TBHP (5 equiv.)	(concentrated)	rt	3 d	decompose
3	NaOH (1.2 equiv.), TBHP (5 equiv.)	CH <sub>2</sub> Cl <sub>2</sub> , H <sub>2</sub> O	rt	1 d	NR
4	Triton B (1 drop), TBHP (5 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	rt	1 min	decompose
5	Bu <sub>4</sub> NOH (0.1 equiv.), TBHP (1.4 equiv.)	THF, H <sub>2</sub> O	0 to rt	1 d	NR
6	<i>n</i> -BuLi (1.1 equiv.), TBHP (1.5 equiv.)	THF	0 to 100	1 d	NR
7	<i>n</i> -BuLi (5.5 equiv.), TBHP (7.5 equiv.)	THF	0 to rt	1 d	NR
8	DBU (3 equiv.), TBHP (5 equiv.)	DCE	100	1 d	NR
9	DBN (10 equiv.), TBHP (10 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	0 to rt	1 d	NR
	VO(acac) <sub>2</sub> (1 equiv.), TBHP (3 equiv.),				
10	2,6-lutidine (1 equiv.)	toluene	rt	2 d	NR
11	DMDO (2 equiv.)	acetone	0	1 h	13c'
12	NaClO (2 equiv.)	diethyl ether, DMF	0	2 h	13c'
13	NMO (2 equiv.)	dioxane	100	1 d	NR
14	NMO (4 equiv.)	dioxane	100	12 h	decompose
15	DBU (1.5 equiv.), <i>m</i> CPBA (3 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	rt to 60	1 d	NR
16	DBU (1.5 equiv.), <i>m</i> CPBA (6 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	60	1 d	SM+S6

17	DBU (6 equiv.), <i>m</i> CPBA (3 equiv.)	DCE	100	1 d	<b>SM+S6</b>
18	K <sub>2</sub> CO <sub>3</sub> (2 equiv.), <i>m</i> CPBA (2 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	rt	1 d	NR
19	KOH (2 equiv.), <i>m</i> CPBA (2 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	rt	1 d	NR
20	KOH (2 equiv.), <i>m</i> CPBA (2 equiv.), 18-C-6 (0.5 equiv.)	CH <sub>2</sub> Cl <sub>2</sub>	rt	1 d	NR
21	KHCO <sub>3</sub> (8 equiv.), <i>m</i> CPBA (4 equiv.)	CH <sub>2</sub> Cl <sub>2</sub> , H <sub>2</sub> O	0	10 min	<b>S6</b>
22	KHMDS (1 equiv.), <i>m</i> CPBA (1 equiv.)	THF	0 to rt	1 d	NR
23	NaOH (10 equiv.), H <sub>2</sub> O <sub>2</sub> (50 equiv.)	THF	rt	1 d	decompose
24	NaOH (1.2 equiv.), H <sub>2</sub> O <sub>2</sub> (5 equiv.)	THF	rt	1 d	decompose
25	<i>t</i> -BuNH <sub>2</sub> (0.5 equiv.), H <sub>2</sub> O <sub>2</sub> (4 equiv.)	MeOH	rt	1 d	NR
26	LiOH (1 equiv.), H <sub>2</sub> O <sub>2</sub> (5 equiv.)	MeOH	rt	16 h	<b>SM+S6</b>
27	NaOH (1.2 equiv.), H <sub>2</sub> O <sub>2</sub> (5 equiv.)	MeOH	rt	0.5 d	NR